MAPT and Alzheimer disease: The AβpE peptide has been identified in early-stage AD, even before clinical symptoms are apparent, implicating it as a potential seeding molecule that may enable pathological Aβ aggregate formation and triggering hyperphosphorylation of tau (6–11).